Stonepine Capital Management LLC Reduces Stake in XOMA Co. (NASDAQ:XOMA)

Stonepine Capital Management LLC trimmed its holdings in XOMA Co. (NASDAQ:XOMA) by 22.0% in the third quarter, Holdings Channel.com reports. The fund owned 195,096 shares of the biotechnology company’s stock after selling 55,033 shares during the period. XOMA comprises 3.3% of Stonepine Capital Management LLC’s portfolio, making the stock its 6th biggest holding. Stonepine Capital Management LLC’s holdings in XOMA were worth $5,166,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA in the first quarter worth about $212,000. Bank of New York Mellon Corp raised its stake in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the period. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Ellsworth Advisors LLC acquired a new stake in shares of XOMA in the third quarter worth $516,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

Insider Buying and Selling

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.20% of the stock is currently owned by corporate insiders.

XOMA Stock Up 1.5 %

XOMA stock traded up $0.50 during trading hours on Wednesday, hitting $34.38. The company’s stock had a trading volume of 3,380 shares, compared to its average volume of 22,115. The company has a market capitalization of $405.00 million, a PE ratio of -9.74 and a beta of 0.90. The stock has a 50 day moving average price of $29.11 and a two-hundred day moving average price of $27.20. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 12 month low of $14.33 and a 12 month high of $35.00.

Analyst Ratings Changes

XOMA has been the topic of a number of research reports. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $117.00 target price on shares of XOMA in a research report on Wednesday, October 23rd.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.